Compare Atmos Energy Corporation (ATO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atmos Energy Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Atmos Energy Corporation trades at $169.29 (market cap $28.59B), while State Street SPDR S&P Biotech ETF trades at $159.23. The key difference: Atmos Energy Corporation pays a 2.36% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Atmos Energy Corporation nearer its low. Which is the better fit depends on your goals.
| ATO | XBI | |
|---|---|---|
Market Cap | $28.59B | — |
Sector | Utilities | Broad Market / Factor |
52-Week High | $192.25 | $164.28 |
52-Week Low | $162.44 | $86.92 |
Enterprise Value | $38.40B | — |
Dividend Yield | 2.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atmos Energy (ATO) trades at $169.68, up 1.05% today, with a bearish technical signal but strong fundamentals including a 28.5% net income margin and consistent dividend payments. Recent Q3 2026 earnings beat estimates with EPS of $1.43 versus $1.35 expected, and the company reaffirmed fiscal 2026 guidance. The stock shows neutral oscillators but bearish moving averages, with key support at $168.
The outlook is mixed: analyst consensus is a Buy with a $190.57 price target, but technical indicators suggest near-term caution. Risks include high capital expenditures impacting cash flow and interest rate sensitivity. Upside potential hinges on execution of rate hikes and infrastructure investments, while downside risks involve regulatory changes and economic slowdowns.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
